StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Mizuho on Cytokinetics (CYTK): 'Investors will now likely shift the debate back to M&A'
December 27, 2023 9:21 AM
Mizuho Securities analyst Salim Syed reiterated a Buy rating and $80.00 price target on Cytokinetics (NASDAQ: CYTK).The analyst comments "This ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Comments
Next Articles
Wall Street bullish on Cytokinetics (CYTK) following positive trial results
December 28, 2023 7:55 AM
Cytokinetics (CYTK) PT Raised to $86 at Truist, 'recent data further support CYTK as an attractive M&A target'
December 27, 2023 1:43 PM
Cytokinetics (CYTK) PT Raised to $107 at Oppenheimer, 'We Stay Bullish'
December 27, 2023 1:42 PM
Oppenheimer on Cytokinetics (CYTK): 'We stay bullish'
December 27, 2023 9:23 AM
Truist on Cytokinetics (CYTK): 'We See Best In Class Potential for aficamten'
December 27, 2023 9:20 AM
B.Riley on Cytokinetics (CYTK): 'Remain Buyers'
December 27, 2023 9:18 AM
Form 8-K CYTOKINETICS INC For: Dec 27
December 27, 2023 7:31 AM
Cytokinetics (CYTK) Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
December 27, 2023 7:30 AM
Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
December 27, 2023 7:30 AM
Cytokinetics (CYTK) to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with HCM
December 26, 2023 4:01 PM
Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopa
December 26, 2023 4:00 PM
